Nigute ushobora kuva muri Saxenda ukajya Wegovy: Igihe, Dose nicyo Witeze

Ibihumbi n’abarwayi batangiye buri munsi Saxenda ubu barabaza ikibazo kimwe: igihe kirageze cyo kwimukira muri Wegovy rimwe mu cyumweru, kandi ni gute switch yakorwa neza? Imiti yombi ni GLP-1 yakira reseptor agonist yakozwe na Novo Nordisk, ariko ikoresha molekile zitandukanye (liraglutide vs semaglutide), injyana ya dose itandukanye hamwe na gahunda zitandukanye. Kubona inzibacyuho neza birinda kwihanganira, bikomeza umuvuduko wo kugabanya ibiro kandi birinda amakosa asanzwe nko gutwikira ibiyobyabwenge byombi.

Niba ushaka umutwe-ku-mutwe reba ibiyobyabwenge bikwiranye nuwuhe murwayi, reba ubuyobozi bwambere, Kugereranya Wegovy na Saxenda: Nuwuhe muti wo kugabanya ibiro birakubereye . Iyi ngingo yibanze ku kintu gitandukanye: inzira ifatika yo kuva muri Saxenda ujya Wegovy, ikubiyemo igihe, gutangira dose, titre hamwe nibyo abarwayi n’amavuriro bagomba kwitega mu mezi yambere.

Impamvu abarwayi bava muri Saxenda berekeza Wegovy

Impamvu zikunze kugaragara abaganga bafata Saxenda kuri Wegovy inzibacyuho ni:

• Kugabanya ibiro byinshi. Mu igeragezwa rya STEP 8 ryateganijwe, abantu bakuru badafite diyabete batakaje hagati ya 15.8% yuburemere bwumubiri kuri semaglutide 2,4 mg buri cyumweru na 6.4% kuri liraglutide 3.0 mg buri munsi mu byumweru 68 (Rubino et al., JAMA 2022).

• Inshinge nke. Gutera inshuro imwe mu cyumweru aho kuba birindwi byorohereza kubahiriza abantu benshi.

• Ikibaya kuri Saxenda. Ikirango cya Saxenda gitanga inama yo guhagarika imiti niba umuntu mukuru atatakaje byibura 4% yuburemere bwibanze nyuma yibyumweru 16, bigatuma abandikirwa benshi basubiramo ubundi buryo.

• Isoko, ibiciro cyangwa ubwishingizi bihinduka , bitandukanye nibihugu kandi bigahinduka kenshi.

Guhindura ntabwo ari itegeko. Amabwiriza yo guhindura abanyamerika muri Reta zunzubumwe z'Amerika avuga ko nta mpamvu yo guhindura umurwayi ukora neza no guta ibiro kuri liraglutide. Icyemezo kigomba guhora kugiti cye.

Saxenda vs Wegovy Dose Urebye

Nk’uko byatangajwe na Leta zunze ubumwe za Amerika zandika amakuru:

Saxenda (liraglutide) yatewe inshinge munsi yumunsi . Itangirira kuri 0,6 mg kumunsi mugihe cyicyumweru kimwe ikazamuka kuri 0,6 mg buri cyumweru (1,2 mg, 1.8 mg, 2,4 mg) kugeza igihe mg 3 yo gufata buri munsi igeze mucyumweru cya 5. Dose yo hasi ni iyitiriwe gusa.

Inshinge za Wegovy (semaglutide) zitangwa munsi yubutaka rimwe mucyumweru , kumunsi umwe buri cyumweru. Gahunda yo kuzamuka ni:

• Icyumweru 1-4: 0,25 mg

• Icyumweru 5–8: 0.5 mg

• Icyumweru 9–12: 1 mg

• Icyumweru 13-16: 1,7 mg

• Icyumweru cya 17 gukomeza: kubungabunga mg 2,4 (bisabwa) cyangwa 1,7 mg

Ikirango cyo muri Amerika kiriho kandi cyemerera abantu bakuru bihanganiye mg 2,4 byibura ibyumweru 4 kwiyongera kugeza kuri mg 7.2 buri cyumweru mugihe hagaragaye ubundi kugabanya ibiro. Dose nimbaraga ziboneka ziratandukanye bitewe nigihugu, burigihe rero ukurikire ikirango cyaho. Kumiterere yukuntu semaglutide ikora, soma Gusobanukirwa inshinge ya Semaglutide nikoreshwa ryayo.

Ibirango byombi bivuga ko ibiyobyabwenge bitagomba guhuzwa nizindi GLP-1 reseptor agonist. Iri tegeko rimwe ryerekana inzira zose zo guhinduranya.

Uburyo bwo Guhindura Saxenda Kuri Wegovy: Intambwe ku yindi

Yaba Wegovy cyangwa ikirango cya Saxenda kirimo Saxenda-kuri-Wegovy yo guhinduranya protocole. Ibikurikira byerekana ubuyobozi bwubuvuzi bwatangajwe hamwe nibikorwa bisanzwe. Uwandikira buri gihe akora umuhamagaro wanyuma.

Intambwe ya 1: Subiramo Impamvu yo Guhindura

Abaganga babanza kwemeza impamvu umurwayi ashaka guhinduka, niba aribwo buryo bwiza, bworoshye, ikiguzi cyangwa ingaruka. Baca basubiramo ibivuguruza. Wegovy ntigomba gukoreshwa mubarwayi bafite amateka yumuntu cyangwa mumiryango ya kanseri ya medullary ya tiroyide cyangwa ABAGABO 2, kandi abantu barwaye diyabete yo mu bwoko bwa 2 bakeneye gukurikirana glucose mugihe cyimpinduka.

Intambwe ya 2: Igihe - Nta Washout ikenewe

Ubuyobozi bufatika bwatangajwe muri Diyabete ya Clinical (Almandoz, Lingvay na Morales, 2020) bwerekana ko umurwayi wihanganira agoniste ya GLP-1 ya buri munsi ku gipimo cyuzuye ashobora gutangira umukozi wa buri cyumweru bukeye bwaho nyuma yo kunywa buri munsi . Serivisi ishinzwe amakuru y’imiti ya Christchurch yo muri Nouvelle-Zélande (2025) nayo ivuga ko nta gihe cyo gutaka gisabwa. Gufata ibiyobyabwenge byombi ntabwo byemewe munsi yikirango.

Hariho ikintu kimwe kidasanzwe. Niba switch ibaho kubera ingaruka mbi za gastrointestinal, ubuyobozi bumwe butanga inama yo guhagarika Saxenda no gutegereza kugeza ibimenyetso bikemutse mbere yo gutangira Wegovy kumupanga muto.

Intambwe ya 3: Hitamo igipimo cyo gutangira

Liraglutide 3 mg buri munsi na dosiye ya semaglutide ntishobora guhinduranya mu buryo butaziguye, kandi nta buringanire bwemewe. Imbonerahamwe yo guhindura ibyasohotse ifata inzira yibitekerezo:

• Abarwayi kuri Saxenda 0,6-1.2 mg buri munsi: mubisanzwe batangira Wegovy kuri 0,25 mg buri cyumweru.

• Abarwayi kuri 1.8-22.4 mg buri munsi: 0,25 mg cyangwa 0.5 mg buri cyumweru.

• Abarwayi bahagaze kuri mg 3 buri munsi: serivisi zimwe (VA, CMIS) zerekana 0.5 mg buri cyumweru nkibintu bitangiriraho label.

Guhera kuri 0,25 mg, nkuko ikirango cya Wegovy kibisaba, gikomeza kwitonda cyane no kuranga-guhuza.

Intambwe ya 4: Kuzamura buri byumweru 4

Guhera ku ntangiriro, Wegovy yazamutse buri byumweru 4 yerekeza kuri mg 1,7 cyangwa mg 2,4. Niba igipimo cyihanganirwa nabi, ikirango cyemerera kuzamuka gukurikira gutinda ibyumweru 4. Kuri dosiye zabuze, label ivuga ko niba ikinini kimwe cyabuze ikindi gikurikira kirenze iminsi 2, bigomba gufatwa vuba bishoboka. Niba inshuro ebyiri cyangwa nyinshi zikurikiranye zabuze, re-kuzamuka kuva kumiti yo hasi irashobora gukenerwa.

Ibyo Gutegereza Nyuma yinzibacyuho

Ingaruka zo mu gifu

Isesemi, impiswi, kuruka no kuribwa mu nda ni ingaruka zikunze kugaragara ku biyobyabwenge byombi. INTAMBWE 8, ibyabaye gastrointestinal byavuzwe na 84.1% byabakoresha semaglutide na 82.7% byabakoresha liraglutide, cyane cyane byoroheje kandi bitagereranywa. Ariko, abitabiriye bake ni bo bahagaritse semaglutide (13.5%) kurusha liraglutide (27,6%). Ifunguro rito, guhagarika kurya iyo byuzuye no kuguma mu mazi bifasha abarwayi benshi muri buri ntambwe nshya.

Kugabanya Ibiro

Kuberako igipimo cya Wegovy gitangiye ari gito, abarwayi bamwe babona kugaruka kwa appetit mucyumweru cya mbere nyuma yo guhagarika mg 3 Saxenda. Ibi mubisanzwe bikemuka uko igipimo kizamuka. INTAMBWE 8, 70.9% by'abitabiriye semaglutide bageze byibuze kugabanuka 10%, ugereranije na 25,6% kuri liraglutide. Ibisubizo biracyaterwa nimirire, ibikorwa na biologiya kugiti cye.

Guhinduka mu maso no mu mubiri

Kugabanuka byihuse, byimbitse birashobora kwerekana gutakaza amajwi murusengero, imisaya na jawline, ibyo bita 'Isura ya Ozempic '. Amavuriro yuburanga aragenda ahuza abarwayi bayobora ibiro hamwe nubuvuzi bwisubiraho. Ingingo yacu Ese abuzuza Dermal bashobora guhindura isura ya Ozempic? Impamvu no kuvura Amahitamo asobanura amahitamo.

Amakosa Rusange Iyo Uhindutse Kuva Saxenda Kuri Wegovy

• Kurenga ibiyobyabwenge byombi. Ntugafate urugero rwa Saxenda rwa nyuma kumunsi umwe ninshinge ya mbere ya Wegovy.

• Gusimbuka neza kuri mg 2,4. Kureka titrasiyo byongera ibyago byo GI ikabije no gukomeretsa impyiko.

• Gufata dosiye zingana. 3 mg ya liraglutide ntabwo 'kimwe na ' igipimo icyo aricyo cyose cya semaglutide.

• Kwirengagiza imiti ya diyabete. Abarwayi kuri insuline cyangwa sulfonylureya barashobora gukenera guhindurwa kugirango birinde hypoglycaemia.

• Gukoresha ibicuruzwa bitemewe 'semaglutide '. Abarwayi bagomba gukoresha gusa ibicuruzwa byemewe, byateganijwe kuva muri farumasi yemewe.

Icyo Ibi bivuze kumavuriro nabatanga

Ku mavuriro yuburanga nubuzima bwiza, izamuka ryubuvuzi bwa GLP-1 buri cyumweru rihindura ingendo zabarwayi. Abarwayi ku micungire y’ibiro by’ubuvuzi akenshi bashakisha uburyo bwo kuvura umubiri, ubwiza bw’uruhu no kugarura amajwi mu gihe cyangwa nyuma ya gahunda yabo. Incamake yacu Isonga ryo Kutabaga Umubiri Kuzuza no Kugenzura Ibipimo byerekana amakarita 2026 aho ibisabwa bigenda.

Ibicuruzwa n'ababigurisha byubaka ibiro-bishinzwe gucunga ibiro bigomba guhuza gusa ubuvuzi bwa GLP-1 bwonyine, buguma bugenzurwa nubuvuzi, hamwe nibicuruzwa byujuje ibisabwa nk'ibyuzuza, ibitera imbaraga za kolagen, mesotherapi hamwe ninshinge zitera umubiri. Kugira ngo wumve uko ubufatanye-label ubufatanye bukora, soma Gucukumbura inshinge za OEM Gutakaza ibiro: Amahirwe yuburyo bwiza kubucuruzi nubuzima bwiza . AOMA ishyigikira abafatanyabikorwa hamwe na GMP ishingiye ku nganda, inyandiko zerekana amabwiriza hamwe no kumenyekanisha ibicuruzwa.

Ibibazo

Nshobora gutangira Wegovy bukeye bwaho inshinge ya Saxenda iheruka?

Akenshi, yego. Ubuyobozi bwatangajwe buvuga ko nta gusakuza bisabwa, kandi buri cyumweru umukozi ashobora gutangira umunsi ukurikira igipimo cyanyuma cya buri munsi. Niba uhinduranya kubera ingaruka mbi, uwandikiwe arashobora kugusaba gutegereza kugeza ibimenyetso birangiye.

Ni ikihe gipimo cya Wegovy natangirana na Saxenda 3 mg?

Ikirango cya Wegovy gitangira abantu bose kuri 0,25 mg buri cyumweru. Serivise zimwe zamavuriro zifata 0.5 mg off-label kubarwayi bahagaze kuri Saxenda 3 mg. Umwanditsi wawe ahitamo ukurikije kwihanganira.

Nshobora gufata Saxenda na Wegovy hamwe?

Oya. Ibirango byombi bivuga ko kubihuza nibindi byose GLP-1 yakira reseptor agonist ntabwo byemewe.

Bifata igihe kingana iki kugirango ugere ku gipimo cyuzuye cya Wegovy?

Kuva kuri 0,25 mg, kugera kuri mg 2,4 bifata ibyumweru 16, hamwe no kubungabunga kuva icyumweru 17. Guhera kuri 0.5 mg bigabanya ibi ibyumweru 4.

Wegovy ikora neza kurusha Saxenda?

Mu igeragezwa rya STEP 8 kumutwe, semaglutide 2,4 mg yatanze ikigereranyo cyo kugabanya ibiro 15.8% ugereranije na 6.4% hamwe na liraglutide 3.0 mg mubyumweru 68. Ibisubizo bya buri muntu biratandukanye.

Kwamagana Ubuvuzi

Iyi ngingo igamije intego rusange yuburezi no kubuvuzi ninzobere mu nganda. Ntabwo ari inama z'ubuvuzi. Saxenda na Wegovy ni imiti yandikiwe gusa. Impinduka iyo ari yo yose yo kuvura, harimo igihe nogukoresha, igomba kugenwa nuwabigenewe abifitemo uruhushya ukurikije amakuru yabigenewe. AOMA ntabwo ikora cyangwa igurisha Saxenda cyangwa Wegovy, nibirango bya Novo Nordisk A / S.

Reba

1. Rubino DM, Greenway FL, Khalid U, n'abandi. Ingaruka za semaglutide ya buri cyumweru vs liraglutide ya buri munsi kuburemere bwumubiri kubantu bakuze bafite umubyibuho ukabije cyangwa umubyibuho ukabije udafite diyabete: INTAMBWE 8 igeragezwa ryamavuriro. JAMA . 2022; 327 (2): 138-150. PMID: 35015037.

2. Almandoz JP, Lingvay I, Morales J, n'abandi. Guhinduranya hagati ya glucagon-isa na peptide-1 reseptor agonist: gushyira mu gaciro no kuyobora. Indwara ya Diyabete . 2020; 38 (4): 390-402. PMID: 33132510.

3. WEGOVY (semaglutide) inshinge / ibinini, Amerika Yandika Amakuru, Novo Nordisk (DailyMed, ivugururwa Kamena 2026).

4. Gutera SAXENDA (liraglutide), Amerika Yandika Amakuru, Novo Nordisk (DailyMed / FDA, 2026).

5. Ishami ry’Amerika rishinzwe ibibazo by’abasirikare. Semaglutide (WEGOVY) kuyobora inshinge zo guhindura inshinge zo kuyobora ibiro, Gashyantare 2023.

6. Serivisi ishinzwe amakuru ya Christchurch. Guhindura kuva liraglutide (Saxenda) ukajya kuri semaglutide (Wegovy), Nyakanga 2025.